Darunavir and Vesicare 5 mg: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
CYP3A inhibition increases antimuscarinic exposure.
Clinical significance and safety
For ritonavir-boosted darunavir (PREZISTA/ritonavir), fesoterodine or solifenacin requires its product-specific restrictions to limit increased adverse effects. The prescriber should check the exact bladder medicine; these are not unrestricted class-wide combinations.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.